免疫原性
基孔肯雅
接种疫苗
病毒学
医学
中和抗体
病毒
血清转化
效价
类病毒颗粒
不利影响
免疫学
抗体
生物
内科学
基因
生物化学
重组DNA
作者
James McCarty,Lisa Bedell,Jason Mendy,Emily E. Coates,Grace Chen,Julie E. Ledgerwood,Sarah Royalty Tredo,Kelly L. Warfield,Jason S. Richardson
出处
期刊:Vaccine
[Elsevier BV]
日期:2023-09-09
卷期号:41 (42): 6146-6149
被引量:5
标识
DOI:10.1016/j.vaccine.2023.08.086
摘要
In a phase 2 safety and immunogenicity study of a chikungunya virus virus-like particle (CHIKV VLP) vaccine in an endemic region, of 400 total participants, 78 were found to be focus reduction neutralizing antibody seropositive at vaccination despite being ELISA seronegative at screening, of which 39 received vaccine. This post hoc analysis compared safety and immunogenicity of CHIKV VLP vaccine in seropositive (n = 39) versus seronegative (n = 155) vaccine recipients for 72 weeks post-vaccination. There were no differences in solicited adverse events, except injection site swelling in 10.3% of seropositive versus 0.6% of seronegative recipients (p = 0.006). Baseline seropositive vaccine recipients had stronger post-vaccination luciferase neutralizing antibody responses versus seronegative recipients (peak geometric mean titer of 3594 and 1728, respectively) persisting for 72 weeks, with geometric mean fold increases of 3.1 and 13.2, respectively. In this small study, CHIKV VLP vaccine was well-tolerated and immunogenic in individuals with pre-existing immunity. ClinicalTrials.gov Identifier: NCT02562482.
科研通智能强力驱动
Strongly Powered by AbleSci AI